What Could Be Propelling Valeant Pharmaceuticals Intl Inc to Decrease?

 What Could Be Propelling Valeant Pharmaceuticals Intl Inc to Decrease?

In today’s session Valeant Pharmaceuticals Intl Inc (VRX) recorded an unusually high (2,363) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the December, 2016 put, expecting serious VRX decrease. With 2,363 contracts traded and 1314 open interest for the Dec, 16 contract, it seems this is a quite bearish bet. The option with symbol: VRX161216P00016500 closed last at: $1.14 or 60.6% up. About 6.98 million shares traded hands. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 51.65% since April 25, 2016 and is downtrending. It has underperformed by 57.66% the S&P500.

Analysts await Valeant Pharmaceuticals Intl Inc (NYSE:VRX) to report earnings on March, 21. They expect $1.34 EPS, down 46.61% or $1.17 from last year’s $2.51 per share. VRX’s profit will be $458.28 million for 3.23 P/E if the $1.34 EPS becomes a reality. After $1.55 actual EPS reported by Valeant Pharmaceuticals Intl Inc for the previous quarter, Wall Street now forecasts -13.55% negative EPS growth.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Ratings Coverage

Out of 23 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 8 rate it a “Buy”, 3 “Sell”, while 12 “Hold”. This means 35% are positive. $310 is the highest target while $11 is the lowest. The $104.42 average target is 503.24% above today’s ($17.31) stock price. Valeant Pharmaceuticals Intl has been the topic of 80 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The rating was upgraded by Mizuho to “Neutral” on Monday, August 15. The rating was downgraded by Rodman & Renshaw on Thursday, November 10 to “Neutral”. IBC downgraded Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Tuesday, October 20 to “Sector Perform” rating. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has “Sector Perform” rating given on Wednesday, March 16 by RBC Capital Markets. The firm has “Neutral” rating by Mizuho given on Friday, October 9. The rating was maintained by Jefferies on Monday, November 2 with “Buy”. The company was maintained on Tuesday, November 17 by Morgan Stanley. Deutsche Bank maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Friday, October 14 with “Hold” rating. Scotia Capital maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rating on Wednesday, October 14. Scotia Capital has “Sector Outperform” rating and $250 price target. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) earned “Buy” rating by Stifel Nicolaus on Wednesday, November 11.

According to Zacks Investment Research, “Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant’s development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.”

Insitutional Activity: The institutional sentiment increased to 0.88 in Q2 2016. Its up 0.02, from 0.86 in 2016Q1. The ratio is positive, as 88 funds sold all Valeant Pharmaceuticals Intl Inc shares owned while 97 reduced positions. 52 funds bought stakes while 107 increased positions. They now own 217.59 million shares or 18.89% less from 268.27 million shares in 2016Q1.
Moreover, Lonestar Cap Ltd Llc has 0.27% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 50,000 shares. Delta Lloyd Nv has 22,319 shares for 0.02% of their US portfolio. First Eagle Management Limited Liability Company owns 380,900 shares or 0.02% of their US portfolio. Fosun Limited accumulated 266,970 shares or 0.52% of the stock. Tower Research Cap Limited Liability (Trc), a New York-based fund reported 6,405 shares. The Ontario – Canada-based Brookfield Asset Management has invested 0.01% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Nebula Capital Management Ltd Partnership has invested 5.07% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Nomura Holdg Inc owns 6.57 million shares or 0.44% of their US portfolio. Advsr Asset Mngmt holds 0.01% or 18,567 shares in its portfolio. Synovus Fin Corporation last reported 1,750 shares in the company. Credit Suisse Ag owns 972,619 shares or 0.02% of their US portfolio. Glenhill Ltd holds 3.28% or 2.26M shares in its portfolio. Blackrock, a New York-based fund reported 32,400 shares. Hap Trading Lc accumulated 2.23% or 1.89M shares. Bb&T Limited Liability holds 23,777 shares or 0.01% of its portfolio.

Insider Transactions: Since June 9, 2016, the stock had 2 insider purchases, and 0 sales for $5.04 million net activity. KARABELAS ARGERIS N bought $98,600 worth of stock or 4,000 shares. The insider PAPA JOSEPH C bought 202,000 shares worth $4.94M.

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company has a market cap of $5.92 billion. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It currently has negative earnings. It operates through two divisions: Developed markets and Emerging markets.

VRX Company Profile

Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.

More notable recent Valeant Pharmaceuticals Intl Inc (NYSE:VRX) news were published by: Profitconfidential.com which released: “Valeant Pharmaceuticals Intl Inc: More Bad News for VRX Stock” on November 24, 2016, also Fool.com with their article: “Why Valeant Pharmaceuticals Intl Inc Stock Is Slumping Today” published on November 08, 2016, Fool.com published: “3 Figures in Focus When Valeant Pharmaceuticals Intl. Inc. Reports Its Q3 Results” on November 01, 2016. More interesting news about Valeant Pharmaceuticals Intl Inc (NYSE:VRX) were released by: Investorplace.com and their article: “Valeant Pharmaceuticals Intl Inc (VRX) Stock Owners Should Ask Tougher Questions” published on November 15, 2016 as well as Profitconfidential.com‘s news article titled: “Valeant Pharmaceuticals Intl Inc: VRX Stock Rises Again” with publication date: November 10, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment